Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.82 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.81 |
| ▸ | IL6 | P05231 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29997135 | 1.00 | TLR7 (0.82) | TLR7NUDT1IL6 | |
| SCHEMBL12175813 | 0.92 | TLR7 (0.78) | TLR7NUDT1IL6 | |
| SCHEMBL18429397 | 0.90 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL19369897 | 0.90 | TLR7 (0.75) | TLR7NUDT1IL6 | |
| SCHEMBL29381054 | 0.90 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL1641626 | 0.90 | TLR7 (1.00) | TLR7NUDT1IL6 | |
| SCHEMBL18429924 | 0.90 | TLR7 (0.74) | TLR7NUDT1IL6 | |
| SCHEMBL822996 | 0.89 | TLR7 (0.72) | TLR7NUDT1IL6 | |
| SCHEMBL20553091 | 0.88 | TLR7 (0.71) | TLR7NUDT1 | |
| SCHEMBL4124603 | 0.88 | TLR7 (0.84) | TLR7NUDT1IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023116413-A1 | METHOD OF DEVELOPING A PEPTIDE-BASED VACCINE CONJUGATED WITH 1V209 | VERSITECH LIMITED (CN) | 2023-06-29 | — | — | WO | disclosed |
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | NEKTAR THERAPEUTICS | 2021-05-06 | — | — | US | disclosed |
| US-20210038742-A1 | CONJUGATION OF TLR7 AGONIST TO NANO-MATERIALS ENHANCES THE AGONISTIC ACTIVITY | HUANG CHING HSIN (US) | 2021-02-11 | — | — | US | disclosed |
| EP-3668548-A2 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | Nektar Therapeutics (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| EP-2563404-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2016-09-21 | — | — | EP | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| WO-2011139348-A9 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2396328-A2 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | The Regents of The University of California (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011139348-A2 | USES OF PHOSPHOLIPID CONJUGATES OF SYNTHETIC TLR7 AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134669-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134668-A1 | PHOSPHOLIPID DRUG ANALOGS | TELORMEDIX SA (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010093436-A2 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | CARSON DENNIS A (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130467-A1 | IMMUNOTHERAPEUTIC TUMOR TREATMENT METHOD | CD274, TLR7, PDCD1LG2 | TLR7 2/4885NUDT1 2779/4885IL6 122/4885 |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | TLR7 20/4885NUDT1 3462/4885IL6 1267/4885 |
| US-20210038742-A1 | CONJUGATION OF TLR7 AGONIST TO NANO-MATERIALS ENHANCES THE AGONISTIC ACTIVITY | TLR7, TLR9, TLR3 | TLR7 1/4885NUDT1 437/4885IL6 985/4885 |
| US-20100210598-A1 | TOLL-LIKE RECEPTOR MODULATORS AND TREATMENT OF DISEASES | TLR3, TLR1, TLR6 | TLR7 9/4885NUDT1 3249/4885IL6 1319/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR7 2/4885NUDT1 2779/4885IL6 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.